Jolynn Tumolo is a journalist writing for Behavioral Healthcare Executive. Her articles cover a range of topics in the field of behavioral healthcare, including research findings, treatment options, and concerns within the industry. Jolynn aims to provide informative and comprehensive coverage of issues related to mental health and well-being.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Jolynn Tumolo's reporting focuses primarily on healthcare and pharmaceuticals, with an emphasis on drug recalls, treatment options, and patient outcomes. Her coverage often cites data or press releases as sources.
Given her focus on medical conditions, medications, and drug recalls, Jolynn would likely be interested in pitches that offer expert analysis of recent studies or clinical trials related to these topics. Additionally, professionals working in the pharmaceutical industry who can provide insights into new treatments or developments may capture her attention.
As she does not have a specific geographic focus mentioned but covers a wide range of medical topics without specified locations attached to them; it is safe to assume she takes an international view of healthcare-related reports.
This information evolves through artificial intelligence and human feedback. Improve this profile .
SAN DIEGO—Patients with primary biliary cholangitis (PBC) treated with obeticholic acid (OCA) in the phase 3 POISE trial had decreased fibrosis
By: Jolynn Tumolo
The comorbidity of depression and sports-related concussion amplifies symptoms of both conditions, according to study findings published in Brain Research.
SAN DIEGO—Real-world data suggest second-line therapy with obeticholic acid (OCA) in patients with primary biliary cholangitis (PBC) who have an
By: Jolynn Tumolo
Methadone was associated with a lower risk of treatment discontinuation than buprenorphine/naloxone among patients with opioid use disorder (OUD), according to study findings published in JAMA.
By: Jolynn Tumolo
Results from a pilot study of patients with narcolepsy provide proof-of-concept evidence that a procedure called targeted lucidity reactivation can be adapted for narcolepsy-related nightmares, a common but often overlooked symptom of the neurological disorder.
SAN DIEGO—Patients are presenting with milder disease but more metabolic complications at the time of primary biliary cholangitis (PBC) diagnosis, compared
By: Jolynn Tumolo
US adults with opioid use disorder (OUD) who received buprenorphine at doses higher than recommended by the Food and Drug Administration (FDA) had significantly lower rates of urgent health care utilization than those whose doses were in line with FDA recommendations. Researchers published their findings online in JAMA Network Open.
The Harvard Drug Group, doing business as Major Pharmaceuticals and Rugby Laboratories, is recalling 3 lots of hydralazine hydrochloride tablets. According to the November 20, 2024, US Food and Drug Administration (FDA) Enforcement Report, samples from the lots failed to meet impurity and degradation specifications during routine stability testing.
(833) 317-6278 
